Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. provided earnings guidance for the six months ended 30 June 2019. The Company's management of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2019, it is expected that the net profit of the Group will record an increase of over 50% for the six months ended 30 June 2019 as compared to that for the six months ended 30 June 2018.